Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Guerri

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Angiology|May 16, 2019
Coronary Intimal Thickening Begins in Fetuses and Progresses in Pediatric Population and Adolescents to AtherosclerosisRoberto Guerri-Guttenberg, Rocío Castilla, Gabriel Cao, et al.
Journal of Global Antimicrobial Resistance|March 14, 2020
Considerations for the optimal management of antibiotic therapy in elderly patientsMarco Falcone, Mical Paul, Giusy Tiseo, et al.
Infectious Diseases and Therapy|December 3, 2021
Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort StudyInmaculada López Montesinos, Silvia Gómez-Zorrilla, Zaira Raquel Palacios-Baena, et al.
Scientific Reports|January 18, 2023
Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patientsMaria Milagro Montero, Max Hardy-Werbin, Soledad Gonzalez-Gallardo, et al.
Journal of Medical Devices|October 12, 2013
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material StrengthConnor Randall, Daniel Bridges, Roberto Guerri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2022
Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource ConsumptionInmaculada López Montesinos, Itziar Arrieta-Aldea, Aitor Dicastillo, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Angiology|May 16, 2019
Coronary Intimal Thickening Begins in Fetuses and Progresses in Pediatric Population and Adolescents to AtherosclerosisRoberto Guerri-Guttenberg, Rocío Castilla, Gabriel Cao, et al.
Journal of Global Antimicrobial Resistance|March 14, 2020
Considerations for the optimal management of antibiotic therapy in elderly patientsMarco Falcone, Mical Paul, Giusy Tiseo, et al.
Infectious Diseases and Therapy|December 3, 2021
Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort StudyInmaculada López Montesinos, Silvia Gómez-Zorrilla, Zaira Raquel Palacios-Baena, et al.
Scientific Reports|January 18, 2023
Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patientsMaria Milagro Montero, Max Hardy-Werbin, Soledad Gonzalez-Gallardo, et al.
Journal of Medical Devices|October 12, 2013
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material StrengthConnor Randall, Daniel Bridges, Roberto Guerri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2022
Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource ConsumptionInmaculada López Montesinos, Itziar Arrieta-Aldea, Aitor Dicastillo, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Pageof 1